Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock

Core Viewpoint - Ocugen, Inc. has announced the pricing of an underwritten offering of 15 million shares of common stock at $1.50 per share, aiming for gross proceeds of $22.5 million, expected to close around January 22, 2026 [1]. Group 1: Offering Details - The offering consists of 15,000,000 shares priced at $1.50 each, resulting in gross proceeds of $22.5 million before expenses [1]. - The offering is led by RTW Investments, with participation from both new and existing investors [1]. - Oppenheimer & Co. is the sole book-running manager for the offering [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for general corporate purposes, capital expenditures, working capital, and general and administrative expenses [2]. Group 3: Company Overview - Ocugen, Inc. is a biotechnology leader focused on gene therapies for blindness diseases, with a modifier gene therapy platform aimed at addressing significant unmet medical needs [5]. - The company is developing programs for inherited retinal diseases and blindness diseases, including retinitis pigmentosa, Stargardt disease, and geographic atrophy [5].